1349 Stock Overview
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., together with its subsidiaries, researches, develops, manufactures, and sells bio-pharmaceutical products.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
My Notes
NewNotes are coming soon
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$3.45 |
| 52 Week High | HK$4.02 |
| 52 Week Low | HK$2.51 |
| Beta | 0.43 |
| 1 Month Change | -0.58% |
| 3 Month Change | 33.72% |
| 1 Year Change | -10.16% |
| 3 Year Change | -23.84% |
| 5 Year Change | -10.62% |
| Change since IPO | 331.25% |
Recent News & Updates
Recent updates
What To Know Before Buying Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (HKG:1349) For Its Dividend
Apr 12
We Think Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) Can Manage Its Debt With Ease
Mar 22Should You Be Adding Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) To Your Watchlist Today?
Mar 07Are Strong Financial Prospects The Force That Is Driving The Momentum In Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.'s HKG:1349) Stock?
Feb 20Could The Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (HKG:1349) Ownership Structure Tell Us Something Useful?
Feb 07Should Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) Be Disappointed With Their 38% Profit?
Jan 25Should You Rely On Shanghai Fudan-Zhangjiang Bio-Pharmaceutical's (HKG:1349) Earnings Growth?
Jan 12Would Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (HKG:1349) Be Valuable To Income Investors?
Dec 28Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) Seems To Use Debt Rather Sparingly
Dec 15Should You Be Adding Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) To Your Watchlist Today?
Dec 03Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.'s (HKG:1349) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
Nov 21Shareholder Returns
| 1349 | HK Pharmaceuticals | HK Market | |
|---|---|---|---|
| 7D | -0.9% | 1.6% | 2.7% |
| 1Y | -10.2% | 3.4% | -6.2% |
Return vs Industry: 1349 underperformed the Hong Kong Pharmaceuticals industry which returned 3.4% over the past year.
Return vs Market: 1349 underperformed the Hong Kong Market which returned -6.2% over the past year.
Price Volatility
| 1349 volatility | |
|---|---|
| 1349 Average Weekly Movement | 4.7% |
| Pharmaceuticals Industry Average Movement | 8.2% |
| Market Average Movement | 7.8% |
| 10% most volatile stocks in HK Market | 15.6% |
| 10% least volatile stocks in HK Market | 3.9% |
Stable Share Price: 1349 is less volatile than 75% of Hong Kong stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: 1349's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 817 | Hai Bo Wang | https://www.fd-zj.com |
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., together with its subsidiaries, researches, develops, manufactures, and sells bio-pharmaceutical products. It offers genetic engineering platform drugs, including CD30-DM1 antibody-drug conjugate (ADC), which is in Phase I clinical trials for tumors; Trop2-SN38 ADC that is in Phase I clinical trials for triple negative, breast, bladder, gastric, and other tumors; Trop2-BB05 ADC that is in pre-clinical studies for lung cancer and triple negative breast cancer; and HER2 ADC that has completed pre-clinical research for metastatic breast and gastric cancers. The company also provides photodynamic technical platform drugs, such as hemoporfin for port wine stain, which is in Phase IV clinical trial; and aminolevulinic acid, which is in Phase II clinical trials for cervical diseases infected by HPV and acne, as well as completed pre-clinical study for brain gliomas.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Fundamentals Summary
| 1349 fundamental statistics | |
|---|---|
| Market Cap | HK$8.54b |
| Earnings (TTM) | HK$151.77m |
| Revenue (TTM) | HK$1.34b |
23.4x
P/E Ratio2.7x
P/S RatioIs 1349 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1349 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.16b |
| Cost of Revenue | CN¥87.05m |
| Gross Profit | CN¥1.07b |
| Other Expenses | CN¥939.91m |
| Earnings | CN¥131.51m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.13 |
| Gross Margin | 92.49% |
| Net Profit Margin | 11.35% |
| Debt/Equity Ratio | 0% |
How did 1349 perform over the long term?
See historical performance and comparison